Evidence map›Paper›PMID 41094083›Full record

ArticleCardiovascular and interventional radiology2026

Safety and Efficacy of High Power (> 100W) Microwave Ablation Using the EMPRINT™ HP System: Final Results of a Post-Market Clinical Follow-Up Study.

Susan van der Lei, Stella van der Wal, Timothy Neuss, Alessandro Serafini, Ludovico Ambrosi, Hannah H Schulz, Danielle J W Vos, Madelon Dijkstra, Florentine E F Timmer, Robbert S Puijk and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Susan van der LeiDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. s.vanderlei@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-6413-476X
Stella van der WalDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Timothy NeussDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Alessandro SerafiniDiagnostic and Interventional Radiology Unit, IRCCS Candiolo Institute, Candiolo, TO, Italy.
Ludovico AmbrosiDiagnostic Imaging and Radiotherapy Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
Hannah H SchulzDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Danielle J W VosDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Madelon DijkstraDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Florentine E F TimmerDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Robbert S PuijkDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Martijn R MeijerinkDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Funding

Medtronic 2023-13450
6 · The paper itself

Abstract

purposeMicrowave ablation (MWA) with higher-power settings (> 100 W) aims to create larger, more uniform ablation zones, potentially reducing local tumour progression (LTP). This post-market clinical follow-up study evaluated the safety and efficacy of higher-power settings for MWA of liver tumours.

methodsPatients with colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC) treated with MWA (> 100 W) using the EMPRINT

resultsOne-hundred-and-twenty-three patients were included. Following 97 procedures for CRLM (82 patients), adverse events (AEs) occurred in 13.4%, with serious AEs (SAEs) in 4.1%. In 44 procedures for HCC (41 patients), AEs occurred in 11.4%, with SAEs in 6.8%. The total SAE rate (5.0%) was lower than the historical cohort (5.8%). For CRLM and HCC, 1-, 2-, and 3-year LTPFS was 94.9%, 93.7%, 93.7%, and 95.1%, 92.5%, 92.5%, respectively. LTP occurred in 4.8% of CRLM (vs. 6.9% in historical cohort; p = 0.38) and in 6.3% of HCC. LC was 100%. Median hospital-stay was 1 day. Median SI was 0.79 for both CRLM and HCC. DISCUSSION: This study indicates that higher-power settings (> 100 W) during MWA for liver tumours does not compromise safety or sphericity of the ablation zone. This was supported by low LTP rates and 100% local control. LEVEL OF EVIDENCE: Level 3.

Indexed as

Carcinoma, HepatocellularCatheter AblationColorectal NeoplasmsLiver NeoplasmsMicrowavesAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedTreatment OutcomeColorectal cancer (CRC)Colorectal liver metastases (CRLM)Hepatocellular carcinoma (HCC)Liver metastasesMicrowave ablation (MWA)Thermal ablation

Identifiers

PMID41094083
PMCPMC12868112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.